PsiOxus Therapeutics announces positive study results of oncolytic vaccine enadenotucirev at 2014 ASCO Annual Meeting

Studies Identify a Phase II Dose and Demonstrate Best in Class Intravenous Delivery Profile Leading to an Expansion of the Clinical Program to New Indications OXFORD, UK and CHICAGO – 3 June, 2014 – PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international

PolyTherics and Antitope form Abzena

New Company Created to be a Leading Provider of Technologies and Services to Enable Better Biopharmaceuticals PolyTherics and Antitope to continue to trade as wholly owned subsidiaries of AbzenaNew brand highlights depth and range of offering to the global biopharmaceutical industryAbzena to establish headquarters in Cambridge, UKLondon, UK, 23 May 2014 – PolyTherics Limited (“PolyTherics”),

BioExtractions Wales completes funding round for innovative extraction service

Mercia Fund Management announces BioExtractions Wales as its latest portfolio company Henley-in-Arden, 19 May 2014. Mercia Fund Management (MFM), a leading provider of investment, incubator space and business support services for fast-growing technology companies, has announced investment in the world’s first and only contract extraction service that uses High Performance Counter Current Chromatography (HPCCC) to

Mercia Fund Management launches flexible, cost effective workspace for early stage gaming and technology businesses

Entrepreneurs take advantage of new tech start-up hub in UK gaming hotspot Henley-in-Arden, 13 May 2014. Mercia Fund Management (MFM), a leading provider of investment and business support services for fast-growing technology companies, has created a high quality workspace targeted at early stage gaming businesses at its Forward House head office in Henley-in-Arden. Mercia Fund

Mercia Fund Management agrees second stage funding for VirtTrade

Digital trading card developer poised for further growth following £280,000 EIS investment Henley-in-Arden, 12 May 2014. VirtTrade has announced the completion of further investment led by Mercia Fund Management (MFM), a leading provider of investment and business support services for fast-growing technology companies. VirtTrade delivers all the fun mechanics of physical card and sticker collecting

Mercia Fund Management backs social media duo Crowd Reactive and TorqBak

Mercia Fund Management expands its digital portfolio with investments in social media display developer Crowd Reactive and social media platform TorqBak Henley-in-Arden, 6 May 2014. Mercia Fund Management (MFM), a leading provider of investment, incubator space and business support services for fast-growing technology companies, has added interactive display developer Crowd Reactive and Twitter marketing and

Thalia Design Automation Ltd completes A round funding and prepares to launch suite of Analog and Power design optimisation tools

Mercia Fund Management and Finance Wales lead significant investment in Electronic Design Automation start-up Henley in Arden, 28th April 2014. Thalia Design Automation Limited (Thalia) today announced completion of its A round funding and imminent beta availability of its range of innovation Electronic Design Automation (EDA) tools. Thalia will provide chip designers with a new

Mercia Fund Management boosts portfolio with Canary investment

Innovative care solution completes investment agreement for over £200,000 Henley-in-Arden, 24 April 2014. Mercia Fund Management (MFM), a leading provider of investment, incubator space and business support services for fast-growing technology companies, has announced Canary Systems Ltd as the latest addition to its technology portfolio. Canary Systems offers a unique solution for elderly people looking

Mercia mention in FT.com “Getting exposure to UK tech”

Our MD contributed to the FT’s recent feature on technology start-ups. The question posed by this feature was whether now is a good time to examine whether the UK’s more specialist technology sectors have something different – and possibly more exciting – to offer, with investors’ appetites cooling towards US technology giants. A renewed investor

PolyTherics and MacroGenics extend Collaboration to Produce Novel Antibody Drug Conjugates

ThioBridge™ linker to attach different payloads to a range of antibodies London, UK, 11 April 2014 – PolyTherics Limited (“PolyTherics”), a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge™ antibody drug conjugate (“ADC”) collaboration with MacroGenics Inc (NASDAQ: MGNX), a US biotechnology company developing